Terms: = Ovarian cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
26 results:
1. Efficacy and safety of VEGF/vegfr inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
2. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract] [Full Text] [Related]
3. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
4. Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis.
Zhao G; Song D; Wu J; Yang S; Shi S; Cui X; Ren H; Zhang B
Front Immunol; 2022; 13():955091. PubMed ID: 36052059
[TBL] [Abstract] [Full Text] [Related]
5. Proapoptotic Effect of Icariin on Human ovarian cancer Cells via the NF-[Formula: see text]B/PI3K-AKT Signaling Pathway: A Network Pharmacology-Directed Experimental Investigation.
Gao J; Fu Y; Song L; Long M; Zhang Y; Qin J; Liu H
Am J Chin Med; 2022; 50(2):589-619. PubMed ID: 35114909
[TBL] [Abstract] [Full Text] [Related]
6. Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
Sköld C; Koliadi A; Enblad G; Stålberg K; Glimelius I
Int J Cancer; 2022 Mar; 150(5):773-781. PubMed ID: 34648676
[TBL] [Abstract] [Full Text] [Related]
7. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/vegfr2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and Theranostic Biomarkers in ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract] [Full Text] [Related]
9. Expression profiles of VEGF-A, VEGF-D and vegfr1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract] [Full Text] [Related]
10. Vasohibin-1 Is a Poor Prognostic Factor of ovarian Carcinoma.
Sano R; Kanomata N; Suzuki S; Shimoya K; Sato Y; Moriya T; Shiota M
Tohoku J Exp Med; 2017 Oct; 243(2):107-114. PubMed ID: 29057763
[TBL] [Abstract] [Full Text] [Related]
11. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
Bjersand K; Seidal T; Sundström-Poromaa I; Åkerud H; Skirnisdottir I
PLoS One; 2017; 12(6):e0179363. PubMed ID: 28609484
[TBL] [Abstract] [Full Text] [Related]
12. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial ovarian cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract] [Full Text] [Related]
13. Expression of Vascular Endothelial Growth Factor in ovarian cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
[TBL] [Abstract] [Full Text] [Related]
14. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract] [Full Text] [Related]
15. Serum angiopoietin-2 and soluble vegfr-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Koponen J; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
BMC Cancer; 2014 Sep; 14():696. PubMed ID: 25245329
[TBL] [Abstract] [Full Text] [Related]
16. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of vegfr-2 and vegfr-3 expression in ovarian cancer patients.
Klasa-Mazurkiewicz D; Jarząb M; Milczek T; Lipińska B; Emerich J
Pol J Pathol; 2011; 62(1):31-40. PubMed ID: 21574104
[TBL] [Abstract] [Full Text] [Related]
18. Cotargeting of vegfr-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
[TBL] [Abstract] [Full Text] [Related]
19. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas.
Näyhä V; Stenbäck F
APMIS; 2008 Feb; 116(2):107-17. PubMed ID: 18321361
[TBL] [Abstract] [Full Text] [Related]
20. Targeting signaling pathways in ovarian cancer.
Reibenwein J; Krainer M
Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
[TBL] [Abstract] [Full Text] [Related]
[Next]
